Implementation of surgeon-initiated Oncotype DX ordering among patients with breast cancer to reduce chemotherapy wait times.

被引：0
|
作者：
Losk, Katya
Freedman, Rachel A.
Lin, Nancy U.
Golshan, Mehra
Lester, Susan
Pochebit, Stephen
Natsuhara, Kelsey
Camuso, Kristen
King, Tari A.
Bunnell, Craig A.
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[5] Brigham & Womens Faulkner Hosp, Boston, MA USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 08期
关键词：
D O I：
10.1200/JCO.2017.35.8_suppl.166
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
166
引用
收藏
页数：2
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF THE USE OF ONCOTYPE DX TO GUIDE ADJUVANT CHEMOTHERAPY DECISIONS IN BREAST CANCER PATIENTS IN MEXICO
    Plun-Favreau, J.
    Suarez, S.
    Chivardy, H.
    Pozo, L.
    VALUE IN HEALTH, 2013, 16 (03) : A140 - A140
  • [22] The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings
    Alkushi, Abdulmohsen
    Omair, Ahmad
    Masuadi, Emad
    Alamri, Ghaida
    Abusanad, Atlal
    Abdelhafiez, Nafisa
    Mohamed, Amin E.
    Abulkhair, Omalkhair
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (02)
  • [23] Predicting Chemotherapy Benefit across Different Races in Early-Stage Breast Cancer Patients Using the Oncotype DX Score
    Shaw, Vikram R.
    Amos, Christopher I.
    Cheng, Chao
    CANCERS, 2023, 15 (12)
  • [24] Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
    Thomas M. Schwedhelm
    Judy R. Rees
    Tracy Onega
    Ronnie J. Zipkin
    Andrew Schaefer
    Maria O. Celaya
    Erika L. Moen
    BMC Cancer, 20
  • [25] Predictors of adjuvant chemotherapy for breast cancer patients with an intermediate Oncotype-DX score: A SEER-based population study.
    Goranta, Sowmya
    Haykal, Tarek
    Bala, Areeq
    AI-Dulaimi, Raqheed
    Bachuwa, Ghassan
    Pandit, Trailokva Nath
    Danish, Rizwan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Role of clinical judgement in offering adjuvant chemotherapy for Breast Cancer patients in conjunction with tumour profiling test - Oncotype Dx: a single breast unit experience
    Patnam, Varun
    Pushdary, Kamal
    Leaver, Nick
    BRITISH JOURNAL OF SURGERY, 2020, 107 : 59 - 59
  • [27] Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016
    Schwedhelm, Thomas M.
    Rees, Judy R.
    Onega, Tracy
    Zipkin, Ronnie J.
    Schaefer, Andrew
    Celaya, Maria O.
    Moen, Erika L.
    BMC CANCER, 2020, 20 (01)
  • [28] The Use of Oncotype DX in Adjuvant Chemotherapy Decision-making in Early Breast Cancer Patients with Intermediate Risk of Mortality at 10 Years
    Ramessur, A.
    Harper-Wyne, C.
    Burcombe, R.
    Jyothirmayi, R.
    CLINICAL ONCOLOGY, 2017, 29 (06) : E103 - E103
  • [29] The impact of delayed implementation of the Oncotype DX® test on patient health outcomes and societal costs for early-stage breast cancer patients
    Levin, L. -A
    Appelberg, K.
    BREAST, 2025, 80
  • [30] Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer
    Wang, Fei
    Reid, Sonya
    Zheng, Wei
    Pal, Tuya
    Meszoely, Ingrid
    Mayer, Ingrid A.
    Bailey, Christina E.
    Park, Ben Ho
    Shu, Xiao-Ou
    CLINICAL CANCER RESEARCH, 2020, 26 (01) : 101 - 109
12345